FDA should improve incentives to lower drug costs, says Dyadic CEO 02-Jul-2019 By Vassia Barba The FDA needs to expedite the approval process to provide incentives for the development of more affordable drugs, says Dyadic CEO.
Merck’s CEO: ‘Huge risk’ taken in drug development requires return 18-Jun-2019 By Vassia Barba Kenneth Frazier argues that the current market dynamics are bringing treatments to patients and the industry does not ‘have to apologise for that.’
BIO EUROPE 2018 BIO: Trump’s Part B pricing scheme ‘undermines the incentive to innovate’ 14-Nov-2018 By Flora Southey We will not stand behind non-competitive pricing schemes that undermine the incentive to innovate and invest in drug development, says BIO VP of industry research, David Thomas.